Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Since its inception in late December 2020 in China, novel coronavirus has affected the
global socio-economic aspect. Currently, the world is seeking safe and effective treatment …

Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has caused hundreds of millions of cases and continues to circulate globally. To establish …

Remdesivir (RDV), a broadly acting nucleoside analogue, is the only FDA approved small
molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports …

The origin of SARS-CoV-2 variants of concern remains unclear. Here, we test whether intra-
host virus evolution during persistent infections could be a contributing factor by …

SARS-CoV-2 remdesivir resistance mutations have been generated in vitro but have not
been reported in patients receiving treatment with the antiviral agent. We present a case of …

Background Severely immunocompromised patients are at risk for prolonged or relapsed
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …

Abstract Coronavirus disease 2019 (COVID-19) infection results in both acute mortality and
persistent and/or recurrent disease in patients with hematologic malignancies, but the …

Analysis of SARS-CoV-2 genetic diversity within infected hosts can provide insight into the
generation and spread of new viral variants and may enable high resolution inference of …

In the absence of effective countermeasures, human convalescent plasma has been widely
used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel …